A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)
The purpose of this study is to look for low levels of oxygen (hypoxia) in lung cancer using
a positron emission tomography (PET) scan. Hypoxia can influence how lung cancer grows and
responds to treatments like radiation therapy and chemotherapy. The use of PET scans to measure
hypoxia may be better and simpler than the approaches used previously. This study will
assess whether or not PET scans can provide useful information about hypoxia in lung cancer.
In this study, a radiotracer called Fluoroazomycin Arabinoside (FAZA) will be used to
measure hypoxia in the patient's tumour. FAZA has already been used in many cancers
including lung cancer. Patients who consent to participate in this trial will receive 1 FAZA
PET Scan prior to their first radiation therapy treatment.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society